What makes RMS’s stem cell therapy for diabetes different from others in development?

Several iPSC-based diabetes therapies are currently in development globally, but RMS’s approach is distinguished by a combination of features that set it apart from the majority of competing programs.

Most significantly, RMS’s therapy is being designed to work without the need for immunosuppressive drugs, a limitation that affects many other cell therapy approaches currently in trials, and which carries serious long-term health risks for patients. RMS is addressing immune compatibility at the level of cell design, through its autologous approach and through engineering strategies in its allogeneic program, rather than relying on systemic immune suppression.

RMS’s therapy also does not require an implantable device, does not use cells derived from human embryos, and is designed to work across all blood types, broadening the potential patient population significantly. It is being developed for both Type 1 and Type 2 diabetes, and is designed with scalability and affordability as explicit goals. This combination, being ethically grounded, clinically practical, and intended for broad accessibility, reflects RMS’s commitment to developing a therapy that is designed to be accessible to the millions of patients who need it.

Learn more about RMS’s approach to diabetes treatment.